Covishield Remained Effective Even During Delta Surge: Lancet Study

The vaccine efficacy in fully vaccinated individuals, said the Lancet, was found to be at 63 per cent.

Covishield vaccine remained effective against moderate-to-severe COVID-19 even during the deadly surge dominated by the highly transmissible delta variant of SARS-CoV-2, according to a study published in The Lancet Infectious Diseases journal.

The Lancet study was meant to evaluate real-world effectiveness of Covishield during the devastating surge between April-May in India that brought the health infrastructure under tremendous strain.

The vaccine efficacy in fully vaccinated individuals, said the Lancet, was found to be at 63 per cent.

During the moderate to severe disease phase, the vaccine efficacy was found to be at 81 per cent, it said.